Medpace Hit with Securities Fraud Lawsuit Over Cancellation Rates

What happened

Medpace Holdings faces a securities fraud lawsuit alleging it misled investors about cancellation rates, leading to a 16% stock decline when the truth emerged. The suit claims the company failed to disclose elevated cancellations that undermined its strong backlog narrative. Medpace's backlog was $2.87B at mid-2025, but the lawsuit highlights that conversion is far from guaranteed if cancellations spike. The company carries no debt and generated strong cash flow, but the legal overhang and renewed scrutiny on cancellations pressure the premium valuation. The master report had already flagged rising cancellations as a key risk, and this lawsuit crystallizes that concern.

Implication

The lawsuit introduces legal and reputational risk that could pressure Medpace's premium multiple, which stood at ~37x TTM earnings. While Medpace's fundamentals remain solid—no debt, strong cash flow, and a large backlog—the litigation may distract management and scare off risk-averse investors. Historically, securities class actions often settle, but the process can take years and incur significant costs, potentially reducing cash available for buybacks. The true test will be whether cancellation rates rise further or if this is a one-time event; investors should demand hard evidence of stable conversion rates. The thesis shifts from neutral to cautious pending clarity on the lawsuit's merits and the company's disclosure practices; we would not add to positions until the dust settles.

Thesis delta

The lawsuit injects immediate downside risk to Medpace's valuation by spotlighting cancellations as a hidden flaw. Previously, the thesis balanced strong execution against variable biotech funding; now, management credibility is in question, shifting the stance toward caution. We downgrade our view from neutral to cautiously bearish until cancellation data and legal outcomes provide clarity.